Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

被引：0

作者：

Zakharia, Yousef

Vlahiotis, Anna

Siu, Gordon

Rao, Dharanija

Teresi, Rosemary

Eccleston, Anthony

机构：

[1] Univ Iowa, Iowa City, IA USA

[2] Pfizer, New York, NY USA

[3] Pfizer Inc, New York, NY USA

[4] Pfizer Inc, Mentor, OH USA

[5] Pfizer Inc, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16553

引用

页数：1

共 50 条

[31] Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Chau, Vincent
Bilusic, Marijo
CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7321 - 7330
[32] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
Shah, Neil J.
Sura, Sneha D.
Shinde, Reshma
Shi, Junxin
Singhal, Puneet
Perini, Rodolfo F.
Motzer, Robert J.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
[33] Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.
Zarrabi, Kevin
Handorf, Elizabeth A.
Miron, Benjamin
Zibelman, Matthew R.
Anari, Fern
Ghatalia, Pooja
Plimack, Elizabeth R.
Geynisman, Daniel M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC) - real world data from a retrospective multi- center analysis
Stelmach, Ramona
Schlack, Katrin
Muhle, Clemens
Darr, Christopher
Neuberger, Stephanie
Reichert, Mathias
Rehlinghaus, Marc
Flegar, Luka
Zengerling, Friedemann
Casuscelli, Jozefina
Cox, Alexander
Nestler, Tim
Egenolf, Timo
Brehmer, Bernhard
Vallet, Sonia
Ivanyi, Philipp
Neuberger, Manuel
Paffenholz, Pia
Grunwald, Viktor
Zschabitz, Stefanie
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 88 - 88
[35] Real-world effectiveness and safety of first-line (1L) avelumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Primary analysis of the AVION study.
Merseburger, Axel Stuart
Baklanova, Olga
Garlonta, Victor T.
Androulakis, Nikolaos E. M.
Christopoulou, Athina
Timotheadou, Eleni
Demey, Wim
Janssen, Jan
Ivanyi, Philipp
Brouwers, Barbara Anna Henk
Wynendaele, Wim
Wang, Lusha
Kostkova, Lenka
Hoffman, Jason
Manzel, Arndt
Koumarianou, Anna
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[36] KEYNOTE-426 Axitinib plus pembrolizumab vs sunitinib in the first-line treatment of metastatic renal cell carcinoma
Bedke, J.
Stuehler, V.
UROLOGE, 2020, 59 (07): : 841 - 842
[37] REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING FIRST-LINE THERAPY IN THE UNITED STATES VETERAN POPULATION
Bhanegaonkar, A.
Kim, R.
Pandya, S.
Wang, L.
Krulewicz, S.
Pennock, G.
Phatak, H.
VALUE IN HEALTH, 2019, 22 : S116 - S116
[38] In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
不详
ONKOUROLOGIYA, 2019, 15 (04): : 140 - 142
[39] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
Wang, Yufei
Zhong, Yichen
Mt-Isa, Shahrul
Perini, Rodolfo
Adejoro, Oluwakayode
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[40] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States (vol 8,e2400132,2024)
Doshi, Gurjyot K.
Osterland, Andrew J.
Shi, Ping
Yim, Annette
Del Tejo, Viviana
Guttenplan, Sarah B.
Eiffert, Samantha
Yin, Xin
Rosenblatt, Lisa
Conkling, Paul R.
JCO CLINICAL CANCER INFORMATICS, 2025, 9

← 1 2 3 4 5 →